Crosspoint Capital Strategies’s AbbVie ABBV Stock Holding History

Crosspoint Capital Strategies’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q1	–	Sell	-48,266	Closed	-$3.15M	–	131
2015 Q4	$3.15M	Buy	48,266 +28,304	+142%	+$1.63M	0.83%	27
2015 Q3	$1.09M	Sell	19,962 -8,074	-29%	-$526K	1.26%	14
2015 Q2	$1.88M	Sell	28,036 -1,339	-5%	-$87.4K	0.54%	42
2015 Q1	$1.72M	Buy	29,375 +4,361	+17%	+$263K	0.83%	36
2014 Q4	$1.64M	Buy	25,014 +14,798	+145%	+$933K	0.57%	47
2014 Q3	$590K	Buy	10,216 +265	+3%	+$14.7K	0.44%	58
2014 Q2	$535K	Sell	9,951 -170	-2%	-$8.92K	0.2%	93
2014 Q1	$520K	Hold	10,121	–	–	0.21%	90
2013 Q4	$522K	Buy	+10,121	New	+$497K	0.17%	100

Other funds holding ABBV

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

JHIU

Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Crosspoint Capital Strategies's ABBV Position: Q1 2016 in Review

Crosspoint Capital Strategies sold out of AbbVie (ABBV) in Q1 2016, closing a stake of 48,266 shares — an estimated $3.15M sold.

Crosspoint Capital Strategies first reported a position in ABBV in Q4 2013 and held it in 9 quarters. The position peaked at $3.15M in Q4 2015. 1,640 funds tracked by Wall St. Rank hold ABBV as of Q1 2016.

Crosspoint Capital Strategies reported no remaining AbbVie position as of Q1 2016 after selling out during the quarter.
Crosspoint Capital Strategies sold 48,266 AbbVie shares in Q1 2016, an estimated $3.15M.
Crosspoint Capital Strategies first reported a position in AbbVie in Q4 2013 and held it in 9 quarters.
Crosspoint Capital Strategies's AbbVie position peaked at $3.15M in Q4 2015.
1,640 funds tracked by Wall St. Rank held AbbVie as of Q1 2016.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2016, filed 16 May 2016.